Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | ECE1 | P42892 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | CTRC | Q99895 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | PTAFR | P25105 | 1/20 | 0.52 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL30887090 | 0.96 | LMNA (0.71) | LMNAECE1NPC1RAB9ACTRC | |
| SCHEMBL5555278 | 0.86 | LMNA (1.00) | LMNAECE1NPC1RAB9ACYP2C9 | |
| SCHEMBL880676 | 0.85 | RAB9A (0.79) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL11949543 | 0.85 | RAB9A (0.79) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1817969 | 0.84 | ECE1 (0.70) | LMNAECE1NPC1RAB9ACTRC | |
| SCHEMBL25003863 | 0.84 | LMNA (0.62) | LMNAECE1NPC1RAB9ACTRC | |
| SCHEMBL5553285 | 0.84 | LMNA (0.65) | LMNAECE1NPC1RAB9ACYP2C9 | |
| SCHEMBL23489730 | 0.84 | ECE1 (0.65) | LMNAECE1NPC1RAB9ACTRC | |
| SCHEMBL30037998 | 0.83 | GPR132 (0.69) | LMNAECE1NPC1RAB9ACTRC | |
| SCHEMBL3497405 | 0.83 | GPR132 (0.69) | LMNAECE1NPC1RAB9ACTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-7666328-B2 | Comprising finely divided particles selected from noble metals, alloys of noble metals, refractory glass compositions, organic medium comprising ethyl cellulose, additional inorganic binder selected from metal oxides, non-oxide borides, non-oxide silicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7303854-B2 | Electrode-forming composition for field emission type of display device, and method using such a composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7276325-B2 | Using photosensitive copper conductive mixture of copper powder in binder; controlling particle sizes | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| CN-1983460-A | Thick film conductor compositions and processing technology thereof for use in multilayer electronic circuits and devices | DU PONT (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20070113952-A1 | Comprising finely divided particles selected from noble metals, alloys of noble metals, refractory glass compositions, organic medium comprising ethyl cellulose, additional inorganic binder selected from metal oxides, non-oxide borides, non-oxide silicides | MICROMAX (US) HOLDINGS LLC | 2007-05-24 | — | — | US | disclosed |
| EP-1788616-A2 | Thick film conductor compositions and processing technology thereof for use in multilayer electronic circuits and devices | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1750286-A1 | Conductor composition for use in LTCC photosensitive tape on substrate applications | E.I.Du pont de nemours and company (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20070023388-A1 | Conductor composition for use in LTCC photosensitive tape on substrate applications | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-02-01 | — | — | US | disclosed |
| CN-1904733-A | Conductor composition for use in LTCC photosensitive tape on substrate applications | DU PONT (US) | 2007-01-31 | — | — | CN | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040191690-A1 | Electrode-forming composition for field emission type of display device, and method using such a composition | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| EP-1447713-A1 | Electrode-forming composition for field emission type of display device and method using such a composition | E.I. du Pont de Nemours and Company (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| EP-0710106-A4 | METHOD OF TREATING ADDICTIVE BEHAVIORS | HITZIG PIETR (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5658955-A | Combined use of dopamine and serotonin agonists in the treatment of immune disorders | HITZIG PIETR (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0710106-A1 | METHOD OF TREATING ADDICTIVE BEHAVIORS | HITZIG, Pietr (US) | 1996-05-08 | — | — | EP | disclosed |
| US-5502080-A | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders | HITZIG PIETR (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1994021244-A1 | METHOD OF TREATING ADDICTIVE BEHAVIORS | HITZIG PIETR (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | LMNA 3496/4885ECE1 3944/4885NPC1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.